comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Beyond glycemia: Comparing tirzepatide to GLP-1 analogues | Reviews in Endocrine and Metabolic Disorders

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

21.38

★★★★☆4.8 (126)

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

21.87

★★★★★4.9 (98)

Results of cardiovascular outcomes trials comparing GLP-1 receptor

22.23

★★★★★5.0 (157)

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms in: Journal of Endocrinology Volume 263 Issue 1 (2024)

23.88

★★★★★4.7 (84)

Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients | Cardiovascular Diabetology

25.77

★★★★★4.9 (203)

It's important to study the difference in GLP-1 medications.⁣ Our analysis found tirzepatide is associated with a lower risk of serious heart and kidney complications compared to dulaglutide in adults with Type

21.33

★★★★★5.0 (176)

GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes

25.64

★★★★★4.8 (132)